Health Care Consultants Publish Research on Cost of Anticoagulant Treatment in the Hospital Setting
August 04, 2014
In the hospital setting, treating patients with the anticoagulant rivaroxaban instead of other anticoagulant therapies is less expensive due to the potential to shorten the hospital length of stay, according to a recent study by a team of health care consultants from Analysis Group and Janssen Scientific Affairs. The study, highlighted in "Rivaroxaban Beats Injectable on Cost-Effectiveness" (Pharmacy Practice News, July 2014), evaluated a hypothetical cohort of 1,636 inpatients, including those undergoing knee or hip replacement as well as those with nonvalvular atrial fibrillation, pulmonary embolism, or deep venous thrombosis in an effort to evaluate the costs from a hospital perspective of treating patients with rivaroxaban versus other anticoagulant agents across the five populations. The Analysis Group team, led by Associate Lynn Huynh and including Vice President Patrick Lefebvre, observed an overall mean cost savings of more than $2.4 million ($1,520 per patient) for all patients who received rivaroxaban. From the hospital perspective, reduction in length of stay contributed to the largest percentage of the total cost savings, while differences in anticoagulant treatment costs led to modest cost savings for both knee and hip replacement surgeries.
Read the article (registration required)
Read the study (subscription required)